Why the study?
Despite available lipid-lowering therapies focusing on LDL, substantial residual cardiovascular risk remains, prompting interest in VLDL as a therapeutic target in ASCVD.
Design
Review
Key result
Interventions aimed at reducing VLDL production or enhancing VLDL metabolism, independent of the LDL receptor, hold promise for lowering cholesterol levels and providing therapeutic benefits beyond LDL in the management of ASCVD.
Authors
Loading...
VLDL-targeted approaches may address residual ASCVD risk; leaves open confirmation in randomized trials.
Targeting VLDL production and metabolism represents a promising LDL receptor-independent strategy for reducing residual cardiovascular risk in patients with ASCVD.
Chen et al. (2024) conducted a review in Atherosclerotic cardiovascular disease (ASCVD). VLDL-targeted therapies (e.g., ANGPTL3 and APOC3 inhibitors) was evaluated. Interventions aimed at reducing VLDL production or enhancing VLDL metabolism, independent of the LDL receptor, hold promise for lowering cholesterol levels and providing therapeutic benefits beyond LDL in the management of ASCVD.